Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). FORWARD-2, an open-label extension study, assessed long-te...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuropsychopharmacology
Main Authors: Thase, Michael E., Stanford, Arielle D., Memisoglu, Asli, Martin, William, Claxton, Amy, Bodkin, J. Alexander, Trivedi, Madhukar H., Fava, Maurizio, Yu, Miao, Pathak, Sanjeev
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6897901/
https://ncbi.nlm.nih.gov/pubmed/31254971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41386-019-0451-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados